{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-01T21:11:58.818224+00:00","company":{"ticker":"SYRE","cik":1636282,"company_name":"Spyre Therapeutics, Inc."},"pagination":{"limit":100,"returned":4,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"executive_change","fact_key":"70b0922a31","cik":1636282,"ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-05-29T20:45:58+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-05-27","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Peter Harwin resigned as Director at Spyre Therapeutics, Inc..","evidence_excerpt":"In addition, effective as of May 27, 2026, Peter Harwin resigned from the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001636282-26-000056","anchor_url":"https://secwatch.observer/filing/0001636282-26-000056#claim-70b0922a31","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000056/0001636282-26-000056-index.htm"},{"fact_type":"earnings_release","fact_key":"355ce8485407595f20dbf7a7c10dab4c5ca41cdb","cik":1636282,"ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-05-05T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first quarter ended March 31, 2026","report_date":"2026-05-05","result_type":"reported_results","revenue_text":null},"claim":"Spyre Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 5, 2026, Spyre Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001636282-26-000051","anchor_url":"https://secwatch.observer/filing/0001636282-26-000051#claim-355ce8485407595f20dbf7a7c10dab4c5ca41cdb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1636282/000163628226000051/0001636282-26-000051-index.htm"},{"fact_type":"material_agreement","fact_key":"d9ca047cbe049c56a5dfea7b8af40c69f6176cf6","cik":1636282,"ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-04-16T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Underwriting Agreement","agreement_type":"underwriting","counterparty":"Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters","effective_date":"2026-04-14","item_codes_triggered":["1.01"],"value_text":"approximately $463.5 million"},"claim":"Spyre Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Guggenheim Securities, LLC, as the representatives of the underwriters valued at approximately $463.5 million (effective 2026-04-14).","evidence_excerpt":"The Underwriting Agreement contains customary representations and warranties, agreements and obligations, conditions to closing and termination provisions.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001628280-26-025508","anchor_url":"https://secwatch.observer/filing/0001628280-26-025508#claim-d9ca047cbe049c56a5dfea7b8af40c69f6176cf6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026025508/0001628280-26-025508-index.htm"},{"fact_type":"earnings_release","fact_key":"75b5b8d23c8dd3ad0dd09aa34b58c89dd242cddb","cik":1636282,"ticker":"SYRE","company_name":"Spyre Therapeutics, Inc.","filed_at":"2026-04-13T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the quarter ended March 31, 2026","report_date":"2026-04-13","result_type":"preliminary_results","revenue_text":null},"claim":"Spyre Therapeutics, Inc. reported preliminary financial results for the quarter ended March 31, 2026.","evidence_excerpt":"the Company expects to report that it had approximately $741 million of cash, cash equivalents and marketable securities as of March 31, 2026","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-26-024906","anchor_url":"https://secwatch.observer/filing/0001628280-26-024906#claim-75b5b8d23c8dd3ad0dd09aa34b58c89dd242cddb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1636282/000162828026024906/0001628280-26-024906-index.htm"}]}